Evidence map›Paper›PMID 37745470›Full record

ArticlebioRxiv : the preprint server for biology2023

Small molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states.

Celeste Riepe, Magda Wąchalska, Kirandeep K Deol, Anais K Amaya, Matthew H Porteus, James A Olzmann, Ron R Kopito

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Celeste RiepeDepartment of Biology, Stanford University, Stanford, CA, USA 94305.
Magda WąchalskaDepartment of Biology, Stanford University, Stanford, CA, USA 94305.
Kirandeep K DeolDepartment of Molecular and Cell Biology, University of California, Berkeley, CA USA 94720.
Anais K AmayaDepartment of Pediatrics, Stanford University, Stanford, CA, USA 94305.
Matthew H PorteusDepartment of Pediatrics, Stanford University, Stanford, CA, USA 94305.
James A OlzmannDepartment of Molecular and Cell Biology, University of California, Berkeley, CA USA 94720.
Ron R KopitoDepartment of Biology, Stanford University, Stanford, CA, USA 94305.
Stanford University · USChan Zuckerberg Initiative (United States) · USUniversity of California, Berkeley · US

Funding

The Ubiquitin Proteasome System in Quality ControlR01GM074874 · NIGMS · STANFORD UNIVERSITY · PI KOPITO, RON R · 2006 to 2022
$8.0M
Lipid droplet regulation and proteome dynamicsR01DK128099 · NIDDK · UNIVERSITY OF CALIFORNIA BERKELEY · PI OLZMANN, JAMES A · 2021 to 2025
$1.6M
Protein Aggregation and Inclusion Body FormationR56NS042842 · NINDS · STANFORD UNIVERSITY · PI KOPITO, RON R · 2007 to 2019
$1.1M
Four Laser, 18 Color Cell Sorter in the SSFFS10RR025518 · NCRR · STANFORD UNIVERSITY · PI HERZENBERG, LEONARD A · 2009 to 2009
$500k
NCRR NIH HHS S10 RR025518NIDDK NIH HHS R01 DK128099NIGMS NIH HHS R01 GM074874NINDS NIH HHS R56 NS042842
6 · The paper itself

Abstract

Over 80% of people with cystic fibrosis (CF) carry the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride ion channel at the apical plasma membrane (PM) of epithelial cells. F508del impairs CFTR folding causing it to be destroyed by endoplasmic reticulum associated degradation (ERAD). Small molecule correctors, which act as pharmacological chaperones to divert CFTR-F508del from ERAD, are the primary strategy for treating CF, yet corrector development continues with only a rudimentary understanding of how ERAD targets CFTR-F508del. We conducted genome-wide CRISPR/Cas9 knockout screens to systematically identify the molecular machinery that underlies CFTR-F508del ERAD. Although the ER-resident ubiquitin ligase, RNF5 was the top E3 hit, knocking out

Identifiers

PMID37745470
PMCPMC10515913
OpenAlexW4386816083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.